Improving Rare Disease Awareness: Paul Wuh-Liang Hwu, MD, PhD

Video

The professor from National Taiwan University Hospital discussed the importance of Rare Disease Day for raising awareness.

“The first step to work on in rare disorders is the diagnosis. In order to increase diagnoses, we need to increase awareness. In order to increase awareness, I think the best way is better education. So, we need to persuade authorities that this education is very important, and they should represent a certain percentage of their continuing education program to cover those rare disorders.”

Monday, February 28, is international Rare Disease Day. Rare diseases affect over 300 million people worldwide, with over 7000 diseases designated as rare.

Companies are developing gene and cell therapies for rare diseases such as Pompe disease and aromatic L-amino acid decarboxylase (AADC) deficiency, including PTC Therapeutics’ gene therapy PTC-AADC. Paul Wuh-Liang Hwu, MD, PhD, professor of pediatrics, National Taiwan University Hospital, serves as investigator on the PTC-AADC trials.

CGTLive spoke with Hwu about Rare Disease Day, rare disease awareness, and physician education. He also discussed the importance of patient advocacy and the improvements that still need to be made in these areas to advance both our understanding and management of rare diseases.

Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Related Content
© 2024 MJH Life Sciences

All rights reserved.